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Abstract
 
During the early stages of thymopoiesis, cell survival is controlled by cytokines that regulate the
expression of antiapoptotic proteins such as Bcl-2. At the pre-T cell stage, a critical checkpoint
for 
 
b
 
 chain selection is monitored by the tumor suppressor p53: pre-T cells can survive and dif-
ferentiate when p53 is removed genetically or when its proapoptotic function is inactivated
physiologically as a consequence of signaling through the pre-T cell receptor complex. Previ-
ous work has shown that the guanine nucleotide binding protein Rho controls cell survival in
T cell progenitors. Here we define the survival pathways controlled by Rho in pre-T cells and
show that this GTPase is a pivotal regulator of the p53-mediated checkpoint operating at the
time of 
 
b
 
 selection: loss of Rho function results in apoptosis in pre-T cells, but this cell death is
prevented by loss of p53. The prevention of cell death by loss of p53 restored numbers of early
T cell progenitors but did not fully restore thymic cellularity. Further analysis revealed that loss
of Rho function caused survival defects in CD4/8 double-positive thymocytes that is indepen-
dent of p53 but can be prevented by ectopic expression of Bcl-2. These studies highlight that
the GTPase Rho is a crucial component of survival signaling pathways in at least two different
thymocyte subpopulations: Rho controls the p53 survival checkpoint in pre-T cells and is also
crucial for a p53 independent survival signaling pathway in CD4/8 double positives.
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Introduction
 
The development and maturation of T lymphocytes in the
thymus is an essential process for the formation of the pe-
ripheral immune system. The progression of T cells
through the early stages of intrathymic differentiation may
be defined by the sequential pattern of expression of a
number of surface markers, including CD44 and CD25
(for review see references 1–3). Initially, cells are CD44
 
1
 
CD25
 
2
 
 (termed DN1); they then go on to acquire CD25
(DN2), when they become committed to the T cell lineage
and begin to rearrange TCR 
 
b
 
 loci. The cells then lose
CD44 expression and continue 
 
b
 
 chain rearrangements to
completion (DN3). At the DN3 pre-T cell stage, cells that
successfully rearrange their TCR 
 
b
 
 locus and express a
functional receptor complex known as the pre-TCR com-
plex proliferate rapidly, downregulate CD25, and differen-
tiate into DN4 cells (3–5). At the next developmental
stage, cells coexpress the receptors for MHCs, CD4 and
CD8, and within the CD4/8 double-positive (DP)
 
1
 
 com-
partment undergo TCR 
 
a
 
 chain rearrangements. Upon
expression of a functional pre-TCR complex, cells are sub-
jected to the processes of positive and negative selection
(for review see references 6 and 7) that ensure the genera-
tion of mature CD4 or CD8 single-positive (SP) T lym-
phocytes that exit to the peripheral lymphatic organs. In
the thymus, the ordered acquisition of antigen receptors
and cytokine receptors allows T cells to survive and
progress to the next developmental stage. Any genetic ma-
nipulation that interferes with thymocyte survival mecha-
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Abbreviations used in this paper:
 
 DP, double-positive; RAG, recombinase-
activating gene; SP, single-positive. 
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nisms has a severe impact on T cell development and ulti-
mately prevents the formation of the peripheral immune
system (8–10). Accordingly, understanding the survival
mechanisms that operate at different stages of thymocyte
development is one key to understanding the complex pro-
cess of thymopoiesis.
In early thymocyte progenitors, binding of IL-7 and
stem cell factor to their respective receptors mediates sur-
vival (11–13). However, once a functional pre-TCR is ex-
pressed on the surface of the cells at the DN3 stage, this
takes over from the cytokines to generate the survival sig-
nals that allow pre-T cells to differentiate and proliferate to
the CD4/8 DP stage (4, 14; for review see reference 13).
The synergistic and overlapping roles of pre-TCR and cy-
tokine signaling in controlling cell survival and differen-
tiation at the DN3 stage has been demonstrated geneti-
cally: mice deficient for the recombinase-activating genes
(RAG), which are unable to rearrange TCR 
 
b
 
 subunits,
are unable to progress beyond DN3 due to lack of a func-
tional pre-TCR; DN3 cells accumulate in the thymi of
these animals (15). In the absence of the common cytokine
receptor gamma chain (
 
g
 
c), which causes loss of IL-7 sig-
naling, DN3 cells are lost and only the DN2 population re-
mains (16).
One critical role for IL-7/
 
g
 
c cytokines in the prevention
of cell death in CD25
 
1
 
 pre-T cells is controlling the expres-
sion of the antiapoptotic protein Bcl-2 (17). The signaling
molecules used by the pre-TCR complex to control sur-
vival are less characterized, although it is known that the
pre-TCR survival checkpoint in DN3 cells is modulated by
the tumor suppressor p53. SCID mice which, similar to
RAG-deficient mice, are unable to rearrange TCR 
 
b
 
 sub-
units, are unable to progress beyond DN3 due to lack of a
functional pre-TCR (18). In the absence of p53, both
SCID (19–21) and RAG (22) null cells are able to generate
CD4/8 DP thymocytes in the absence of TCR 
 
b
 
 selection.
Similarly, mice defective in expression of the CD3
 
g
 
 sub-
unit, an important structural and signaling component of
the pre-TCR, show a severe block at DN3 due to increased
apoptosis, but crossing onto a p53
 
2
 
/
 
2
 
 background strikingly
alleviates this block (23). Accordingly, a model has been
proposed in which p53 acts as a sensor for correct 
 
b
 
 selec-
tion. Cells can only move forward from the DN3 stage
when p53 is removed genetically or inactivated physiologi-
cally. Signaling through the pre-TCR complex, a process
absolutely dependent on successful rearrangements of the
TCR 
 
b
 
 locus, is crucial to prevent p53-mediated apoptosis.
Previously, we examined the role of the guanine nucle-
otide binding protein Rho in the thymus (24–26). The
bacterial enzyme, C3 transferase from 
 
Clostridium botulinum
 
,
selectively ADP-ribosylates Rho within its effector-binding
domain and abolishes its biological function. By using the
proximal p56lck promoter to drive thymocyte-specific ex-
pression of C3 transferase, it was possible to produce trans-
genic mice in which the first thymocyte progenitors and
subsequent subsets were devoid of Rho function. Rho inac-
tivation severely impairs the generation of normal numbers
of thymocytes and peripheral T cells in lck-C3–transgenic
mice (24, 26). The most striking problem in lck-C3–trans-
genic mice is that early CD25
 
1
 
 thymocyte progenitors un-
dergo massive apoptosis at the DN2 and DN3 stage, which
leads to severe depletion of these and subsequent thymic
subpopulations. There is a second defect in the lck-C3
mice: the few DN4 cells that do develop show decreased
rates of cell cycle progression that contribute to the failed
expansion and development of CD4/8 DP and SP thy-
mocytes.
As discussed, the DN2 and DN3 cells that die without
Rho function are normally dependent on their survival by
overlapping signals generated by the IL-7 receptor and the
pre-TCR. It is not known whether cells lacking Rho func-
tion have defects in the ability of the pre-TCR to control
cell survival, particularly the p53 checkpoint, or the ability
of IL-7 to control cell survival by regulating Bcl-2 expres-
sion. In this context, we previously described that the loss
of cellularity caused by loss of Rho function in the thymus
can be restored by ectopic expression of a Bcl-2 transgene
(24). There is also a striking rescue of DN2 and DN3 thy-
mocyte progenitors by the ectopic expression of Bcl-2.
One simple interpretation of this result is that cell death in
the Rho-deficient CD25
 
1
 
 cells is caused by failure in IL-7
receptor signaling to upregulate normal levels of Bcl-2.
The Bcl-2 experiments in the Rho-deficient thymi provide
strong evidence that the defect caused by loss of Rho func-
tion is a survival defect but it does not mean a priori that
the original cellular defect was loss of Bcl-2. Moreover, the
Bcl-2 experiments cannot diagnose whether Rho is regu-
lating death by controlling the p53 checkpoint in pre-T
cells. The relationship between Bcl-2 and p53 in thymus
survival is indeed complex. Overexpression of Bcl-2 has
been demonstrated to protect DP thymocytes against p53-
mediated apoptosis induced by DNA damage (27). How-
ever, Bcl-2 expression is not sufficient to prevent cell death
in pre-TCR–deficient T cell precursors (23, 28).
The object of this study was to explore genetically the
possibility of a link between Rho and p53 in the control of
pre-T cell survival. We now show that the apoptosis de-
fects caused by loss of Rho function in CD25
 
1
 
 cells are al-
leviated on a p53
 
2
 
/
 
2
 
 background. That is, the loss of Rho
function only causes apoptosis in early thymocyte progeni-
tors in the presence of p53. Our results thus identify the
GTPase Rho as a regulator of the p53 survival checkpoint
during thymopoiesis. We also show that Rho has a role in
DP thymocyte survival, but in contrast to the pre-T cell
population, this role is independent of p53.
 
Materials and Methods
 
Mice.
 
Mice were bred and maintained under specific patho-
gen–free conditions in the Imperial Cancer Research Fund Bio-
logical Resources Unit. Transgenic mice expressing the 
 
C3 botuli-
num
 
 C3 transferase gene in the thymus under the control of the
p56lck promoter were generated as previously described (24, 26).
Mice homozygous null for the p53 gene were provided by A.
Bradley (Howard Hughes Medical Institute, Baylor College,
Houston, TX). E
 
m
 
-Bcl-2 mice (strain Bcl-2-25), expressing hu- 
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man Bcl-2 in the thymus and peripheral T cell compartments,
were a gift from S. Cory (The Walter and Eliza Hall Institute of
Medical Research, Melbourne, Australia). Litters were typed for
inheritance of the transgenes/p53
 
2
 
/
 
2
 
 mutation by PCR of ge-
nomic DNA.
 
PCR.
 
Transgene-carrying mice were identified by PCR using
transgene-specific primers: C3, G9112 (GCCACCATGGAGCAG-
AAGCTGATCTCCGG) and C3NT (CTGATTTGCTTAG-
TCCATAC) or MO142 (GCGCTTACCTGTAGGCATTGC)
and C3CT (GGGCACAGCTATCAATCC); Bcl-2, Bcl-2-1
(GGAACTGATGAATGGGAGCAGTGG) and Bcl-2-2 (GCA-
GACACTCTATGCCTGTGTGG); and p53, 5NTL (GTGG-
GAGGGACAAAAGTTCGAGGCC) and 3WTL (ATGGGAG-
GCTGCCAGTCCTAACCC) and F8NEO (TCTCCTGTCA-
TCTCACCTTGC). Genomic DNA was purified from mouse ear
punches (or tail snips for p53) and used as template for 35 cycles of
PCR (57
 
8
 
C annealing, 72
 
8
 
C elongation, 95
 
8
 
C denaturation).
 
Cell Preparation.
 
Thymi were obtained by dissection from
4–6-wk-old mice. Tissue was disaggregated by mincing with fine
forceps and forced through a fine mesh filter to obtain a single-
cell suspension. Total cell numbers were determined by micro-
scopic observation using a Neubauer hemocytometer.
 
Flow Cytometric Analysis.
 
Antibodies (PharMingen) were ob-
tained conjugated to FITC, PE, or biotin. Biotinylated antibodies
were revealed using streptavidin–TRI-COLOR (Caltag Labs.) or
streptavidin–allophycocyanin (Molecular Probes). Thymocytes
were stained for surface expression of CD8 (53-5.8), CD4
(RM4-5), CD25 (7D4), CD44 (IM7), B220 (RA3-6B2), Mac-1
(M1/70), Gr-1 (RB6-8C5), CD3
 
g
 
 (145-2C11), 
 
a
 
/
 
b
 
 TCR (GL-
3), pan-NK (DX5), anti–mouse Bcl-2 (PharMingen), and Thy1.2
(53-2.1). Cells were stained with saturating concentrations of an-
tibody at 4
 
8
 
C for 20 min at 2 
 
3 
 
10
 
6
 
 cells per sample in a 96-well
V-bottomed microtiter well plate in 100 
 
m
 
l of PBS containing
1% BSA. Cells were washed with this buffer between incubations
and before analysis on a FACSCalibur™ (Becton Dickinson).
Events were collected and stored ungated in list mode using
CELLQuest™ software (Becton Dickinson). Live cells were
gated according to their forward and side scatter profiles, and data
were analyzed using CELLQuest™ software.
 
Intracellular Staining.
 
Thymocytes were isolated and surface
receptors were stained as described above. Cells were fixed in 1%
paraformaldehyde in PBS for 10 min at room temperature,
washed in PBS, and permeabilized with 0.3% saponin permeabili-
zation buffer (0.3% vol/wt saponin, 5% FCS, and 10 mM Hepes,
pH 7.4, in PBS) for 10 min at room temperature. Permeabilized
cells were then washed, incubated with an anti-Fc
 
g
 
RII blocking
mAb, and stained with an antibody to the intracellular protein of
interest. All washes after permeabilization were performed in sa-
ponin wash buffer (0.1% vol/wt saponin, 5% FCS, and 10 mM
Hepes, pH 7.4, in PBS).
 
Apoptosis Assay.
 
Apoptosis within thymic subpopulations was
assessed using two protocols: exclusion of 7-amino actinomycin
D (7AAD) and plasma membrane staining using annexin V (29).
For 7AAD analysis, thymocytes were stained with the appropriate
fluorochrome-labeled antibody in DMEM/25 mM Hepes sup-
plemented with 10% FCS. After washing, cells were incubated
with 7AAD (Calbiochem-Novabiochem) for 20 min at 4
 
8
 
C in
the dark. Cells were analyzed by flow cytometry, with apoptotic
cells being identified by 7AAD staining as described (30). For the
annexin V staining, thymocytes were stained with the appropriate
fluorochrome-labeled annexin V buffer (10 mM Hepes/NaOH,
pH 7.4, 140 mM NaCl, 2.5 mM CaCl
 
2
 
) in conjunction with 2.5
mg/ml annexin V-bio (PharMingen), washed, and revealed with
streptavidin–TRI-COLOR. For the analysis of thymocyte apop-
tosis over extended periods of time, cells were cultured in RPMI,
10% FCS, and 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME at 5% CO
 
2
 
 before staining.
 
Results
 
Rho-mediated pre-T Cell Thymocyte Survival Is Controlled
by p53.
 
C3-mediated ablation of Rho function in lck-
C3–transgenic mice leads to increased levels of apoptosis in
CD25
 
1
 
 T cell progenitors, resulting in their elimination
and a corresponding depletion of all subsequent develop-
mental stages in the thymus (24). To investigate if cell
death caused by the loss of Rho function in pre-T cells was
mediated by p53, we examined the consequences of p53
deletion on survival of Rho-deficient thymocytes. Accord-
ingly, p53 knockout mice were crossed with the lck-C3–
transgenic mice, and the p53 heterozygous offspring were
backcrossed to produce mice expressing the C3 transgene
on a p53
 
2
 
/
 
2
 
 background. Thymocytes from the different
mice were then analyzed for the presence of the CD25
 
1
 
pre-T cell subset. The data in Fig. 1 A show CD44 and
CD25 immunofluorescence analysis of thymocyte progeni-
tors within the CD4/8 DN subset of thymocytes. p53
 
2
 
/
 
2
 
thymocytes have a normal distribution of the DN1-4 T cell
progenitors, whereas the depletion of CD25
 
1
 
 cells in the
Rho-deficient thymi is readily demonstrated. Strikingly,
CD25
 
1
 
 thymocytes were present in the lck-C3/p53
 
2
 
/
 
2
 
double transgenics. Moreover, numerical analysis con-
firmed the rescue of the CD25
 
1
 
 pre-T cell population in
lck-C3/p53
 
2
 
/
 
2
 
 double transgenics (Fig. 1 B). The loss of
p53 thus prevents the apoptosis induced by loss of Rho
function and rescues CD44
 
2
 
25
 
1
 
 pre-T cells. Although the
CD25
 
1
 
 population is restored by the loss of p53 in the lck-
C3 transgenics, the CD44/25 staining profiles in Fig. 1
show that these cells fail to accumulate normal levels of
DN4 cells. This reflects that loss of Rho function partially
inhibits and delays cell cycle progression in DN4 cells,
thereby preventing their expansion to normal levels (24).
The proliferation of DN3 and DN4 cells is dependent
on the successful rearrangement and expression of TCR 
 
b
 
chains. We therefore wished to exclude the possibility that
loss of p53 in the Rho-deficient thymi was allowing sur-
vival of non–
 
b
 
-selected pre-T cells. Intracellular staining of
DN3 cells with an antibody reactive to a common 
 
b
 
 chain
epitope (31) quantitates levels of intracellular 
 
b
 
 subunits
and thus monitors successful 
 
b
 
 chain rearrangements. The
results show the presence of normal levels of intracellular 
 
b
 
chains in CD44
 
2
 
25
 
1
 
 cells from lck-C3/p53
 
2
 
/
 
2
 
 mice, indi-
cating that they have apparently undergone normal 
 
b
 
 selec-
tion (Fig. 2).
 
Rho Is Not Required for Bcl-2 Expression in pre-T Cells.
 
The expression of the survival protein Bcl-2 is develop-
mentally regulated in the thymus (17, 32) and normally up-
regulated in CD25
 
1
 
 pre-T cells as a consequence of signal-
ing by the IL-7 receptor (17, 28, 33). Our previous
observations that ectopic Bcl-2 could prevent apoptosis in
Rho-deficient CD25
 
1
 
 cells prompted speculation that Rho 
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might be a critical component of pathways that link the IL-7
receptor to the control of Bcl-2 expression. Indeed, it has
been shown in transformed T cell lines that Rho signaling
pathways can regulate intracellular levels of Bcl-2 (34). Pre-
viously, we did not attempt to examine Bcl-2 levels in
Rho-deficient CD25
 
1
 
 cells because they are apoptotic, and
hence changes in the expression of Bcl-2 might occur as a
consequence of apoptosis rather than its cause. However,
in lck-C3/p53
 
2
 
/
 
2
 
 mice, we prevent the induction of apop-
tosis in the CD25
 
1
 
 population so that sufficient numbers of
viable cells are available for examination. Fig. 3 shows im-
munofluorescence analysis of intracellular Bcl-2 levels in
permeabilized DN thymocytes. The data show the pattern
of Bcl-2 upregulation at the different stages of early thy-
mocyte development and reveal that intracellular levels of
Bcl-2 in pre-T cells are indistinguishable among wild-type,
p53
 
2
 
/
 
2
 
, and lck-C3/p53
 
2
 
/
 
2
 
 mice. These results demon-
strate that Rho function is not required for Bcl-2 expres-
sion in the thymus.
 
Loss of Rho Function Results in Increased Apoptosis in CD4/8
DPs by p53-independent Pathways.
 
This study shows that
the cell death initiated by loss of Rho function in pre-T
cells can be prevented by the removal of p53. However,
despite this rescue within the pre-T cell compartment, ex-
amination of the gross morphology of the thymus and of
total thymocyte numbers revealed that the absence of p53
did not restore cellularity in lck-C3 transgenics (Table I).
This result is different from the results seen when ectopic
Bcl-2 is used to prevent cell death in lck-C3–transgenic
mice. These results were published previously and revealed
that overexpression of Bcl-2 in lck-C3–transgenic mice re-
stored the pre-T cell population to normal levels but also
partially rescued total thymic cellularity (24). One explana-
tion for this discrepancy is that Rho is required for survival
Figure 1. (A) Analysis of CD4/8 DN thymocyte popu-
lations in lck-C3/p532/2 mice. Thymi were removed and
thymocytes were isolated from p531/2, p532/2, lck-C3/
p531/2, and lck-C3/p532/2 transgenic mice and analyzed
for expression of CD25 and CD44 by lineage exclusion of
all CD4/8 DP and SP thymocytes as well as all cells of
non–T cell lineage using a panel of biotinylated antibodies
(CD4bio, CD8bio, CD3bio, B220bio, Mac-1bio, NKbio,
gd-bio, and Gr-1bio) revealed with streptavidin–TRI-
COLOR, and costained with anti-CD44–PE, anti-CD25–
FITC, and Thy1–allophycocyanin. (B) Cell number of
CD25/44 thymic populations in lck-C3/p532/2 mice.
Absolute cell numbers of CD441252, CD251, and
CD442252 were calculated from p531/2, p532/2, lck-C3/
p531/2, and lck-C3/p532/2 transgenic mice. Thy1.2 was
used to eliminate non-T cells from the numerical analysis. 
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of thymocytes at later stages of development and that these
later pathways for thymocyte survival are p53 independent
but can be modulated by Bcl-2. In this context, not only
are the lck-C3 thymi extremely small but they also have a
very abnormal ratio of CD4/8 DPs and SPs. Typically, DPs
should represent 80% of total thymocytes, but in lck-C3
thymi, they approximated 50% of the population. SPs in a
normal mouse usually represent 15% of normal thy-
mocytes, whereas in lck-C3 thymi, they were frequently
30–40% of the total population. It should be remembered
that total numbers of thymocytes in lck-C3 thymi are se-
verely reduced, so the skewing of DP to SP percentages
does not mean that there are more SPs in the lck-C3
thymi. However, the skewing of the ratios of DPs/SPs in-
dicated that there might be selective depletion of DPs in
the lck-C3–transgenic mice. We have never before looked
at the effects of Rho inhibition on the survival characteris-
tics of DPs. The data in Fig. 4, A and B, address this point.
Cells were analyzed by flow cytometry, with apoptotic
cells being identified by 7AAD staining (30) and with an-
nexin V (29). The results revealed an increase in apoptotic
cells in the CD4/8 DPs isolated from lck-C3–transgenic
mice compared with wild-type controls. The data in Fig. 4
D show that the loss of p53 did not prevent apoptosis in
CD4/8 DPs from lck-C3–transgenic mice, which was in
marked contrast to the protective effect of p53 removal on
the cell death caused by loss of Rho function in DN cells
(Fig. 4 C). Strikingly, the increased rate of cell death in
DPs is reduced to wild-type levels in the lck-C3/Bcl-2
double transgenics (Fig. 5 A). We had hypothesized that
Figure 2. Intracellular b chain staining of CD251 thymocytes from
lck-C3/p532/2mice. Thymocytes from p531/2, p532/2, and lck-C3/
p532/2 transgenic mice were stained with anti-CD25–PE and a panel of
biotinylated antibodies (CD4bio, CD8bio, CD3bio, B220bio, Mac-1bio,
NKbio, gd-bio, and Gr-1bio) revealed with streptavidin–TRI-COLOR
before saponin permeabilization and staining with an antibody to the
common  b chain epitope.
Figure 3. Intracellular Bcl-2 levels in different thymic subsets of lck-C3/p532/2 mice. Thymocytes from p531/2, p532/2, and lck-C3/p532/2 trans-
genic mice were stained with anti-CD25–PE, CD44–Cy-Chrome, and a panel of biotinylated antibodies (CD4bio, CD8bio, CD3bio, B220bio, Mac-
1bio, NKbio, gd-bio, and Gr-1bio) revealed with streptavidin–allophycocyanin before saponin permeabilization and staining with an antibody to murine
Bcl-2 (open histograms). The grey shaded areas represent the staining of an isotype-matched control antibody.82 Rho Controls a p53-dependent Survival Checkpoint during Thymopoiesis
increased cell death was responsible for selective loss of DPs
in lck-C3–transgenic mice and hence responsible for the
skewed ratio of DP/SP seen in lck-C3 mice (Fig. 5 B).
Consistent with this hypothesis, cell death in DPs was pre-
vented by ectopic expression of Bcl-2, and the ratio of DP/
SP in the lck-C3 mice was restored to normal (Fig. 5 B).
Expression of Bcl-2 also resulted in an increase in the total
numbers of DP thymocytes: normally, there are only 4–6
million DPs in lck-C3 mice, compared with 100–150 mil-
lion DPs in normal littermate controls. Expression of Bcl-2
in the lck-C3 mice restored DPs to 26–34 million. Total
numbers of SPs were not changed by Bcl-2 expression.
Discussion
Loss of Rho function in CD251 pre-T cells results in
cell death and the depletion of this population from the
thymus. Pre-T cells are dependent for survival on a com-
plex network of overlapping signals generated by cytokines
and the pre-TCR. There is also evidence that cell death in
T cell precursors involves signaling by ‘death’ receptors of
the TNF receptor (TNFR) family that signal via the
adapter Fas-associated death domain protein (FADD)/
MORT1 (35). As T cells undergo b chain rearrangements,
there is a checkpoint that ensures that only cells that are
correctly b selected survive and develop into mature T
cells. This checkpoint is monitored by the tumor suppres-
sor p53. This study has explored the role of Rho in con-
trolling p53-mediated apoptosis in the thymus. We have
shown previously that when Bcl-2 is ectopically overex-
pressed, loss of Rho function no longer causes cell death
within the pre-T cell population. Cell survival is controlled
by a delicate balance between proapoptotic and antiapop-
totic signals: overexpression of Bcl-2 pushes the balance in
favor of survival (36) but does not mean a priori that the
original cellular defect was loss of Bcl-2. Indeed, we show
herein that loss of Rho function does not prevent induc-
tion of Bcl-2 in pre-T cells. The upregulation of Bcl-2
during early thymocyte development is regulated by IL-7
(17, 28, 33). The presence of normal Bcl-2 levels in thy-
mocytes lacking Rho function is an indication that at least
one IL-7–mediated signal for survival operates normally in
the absence of Rho. The other main survival pathway in
pre-T cells is monitored by p53 (23). Our results demon-
strate that Rho controls the cell death response initiated by
p53; in the absence of p53, loss of Rho function no longer
results in cell death within the pre-T cell population. These
data reveal Rho to be a critical component of the signal
transduction pathways used to control the proapoptotic
p53 checkpoint during TCR b selection.
Previous work has indicated that the pre-TCR complex
Table I. Cellularity of lck-C3/p532/2 Double Transgenics
Mouse Total thymocytes
3106
p531/2 196 6 23
p532/2 202 6 16
lck-C3/p531/2 9.92 6 3.3
lck-C3/p532/2 11.9 6 6.1
Thymi were removed and the number of thymocytes was determined
from p531/2, p532/2, p531/2/C3, and p532/2/C3 transgenic mice.
Figure 4. The DN thymic subset is rescued from apop-
tosis in lck-C3/p532/2 double-transgenic mice. (A) Thy-
mocytes were isolated from 4–6-wk-old mice and placed
in culture for 6 h. Cells were stained with CD4–PE, CD8–
FITC, and 7AAD to identify apoptotic DP thymocytes.
(B) Thymocytes were prepared as in A, stained with CD8–
FITC, CD4–PE, Thy1.2–allophycocyanin, and annexin
V-bio, which was revealed using streptavidin–TRI-
COLOR. (C) Rescue from apoptosis of DN thymocytes
in lck-C3/p532/2 mice. (D) Failure to rescue DP thy-
mocytes from apoptosis in lck-C3/p532/2 double-trans-
genic mice. WT, wild type.83 Costello et al.
controls p53-dependent cell survival in DN3 cells (23). We
now know that Rho also functions to prevent p53-medi-
ated cell death in the thymus. However, we do not think
that Rho is in a linear signaling pathway from the pre-
TCR complex to counter p53 induction of cell death. We
rather view that Rho is part of a parallel system operating
in conjunction with the pre-TCR to regulate survival at
the DN3 stage. This conclusion is based on a number of
experiments that reveal differences between pre-TCR–
mediated survival and Rho-mediated survival. First, the sur-
vival defect caused by loss of Rho function in DN thy-
mocytes can be rescued by ectopic expression of Bcl-2,
whereas pre-TCR–mediated defects cannot. Second, block-
ade of signaling by death receptors prevents apoptosis in
RAG-deficient mice lacking a pre-TCR (35) but not in
Rho-deficient thymi (37).
Interestingly, the genetic removal of p53 allowed pre-T
cells to survive in the absence of Rho function, but this did
not restore thymocyte cellularity. Elimination of p53 is thus
not sufficient to compensate for lack of Rho function dur-
ing all stages of thymocyte development. In contrast, ex-
pression of Bcl-2 in Rho-deficient thymi allows survival of
pre-T cells and quite significantly reconstitutes total thymic
cellularity. The discrepancy between the magnitude of the
rescue achieved by Bcl-2 expression versus p53 loss
prompted us to search for Rho-regulated, Bcl-2–sensitive
but p53-independent survival responses in the thymus. This
search resulted in the discovery that Rho function is re-
quired for optimum survival of CD4/8 DPs in lck-C3
mice. In this respect, CD4/8 DPs, like pre-T cells, are quite
sensitive to p53-mediated apoptosis (38). Nevertheless, loss
of p53 had no influence on the level of cell death caused by
loss of Rho function in DPs, whereas expression of Bcl-2
was able to alleviate this problem. The picture to emerge
from these studies is that Rho is a crucial component of sur-
vival signaling pathways in at least two different thymocyte
subpopulations: Rho controls the p53 survival checkpoint
in pre-T cells and is also crucial for p53-independent sur-
vival signaling pathways in CD4/8 DPs. There is one caveat
about studies of DPs and SPs in lck-C3 mice, which is that
any cell that reaches these developmental stages in the lck-
C3 mice has survived the Rho-regulated p53 checkpoint in
early progenitors. This could be because the cells compen-
sate for loss of Rho (39), in which case we would underes-
timate the functional properties of Rho in DPs and SPs.
Finally, this study defines Rho function on the basis of
sensitivity to Clostridium botulinum C3 transferase. The
specificity of C3 transferase for Rho and its failure to target
Rac1, Rac2, or Cdc42 is well documented. However,
multiple isoforms of Rho exist, and each Rho isoform has
the potential to interact with a number of different effec-
tors. A future challenge will be to establish whether the
heterogeneity of Rho function in the thymus reflects the
expression of different Rho isoforms or different Rho ef-
fectors in the various thymocyte subsets.
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